Synonyms: AZ-13337019 | AZ13337019 | Movantik® | Moventig® | NKTR-118
naloxegol is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Naloxegol is a PEGylated version of naloxol (α-naloxol PubChem CID 5492271; β-naloxol PubChem CID 5492293). PEGylation reduces the compound's ability to cross the blood-brain barrier, therefore restricting CNS penetration. Naloxegol is termed a peripherally acting μ-opioid receptor antagonist, or PAMORA. The synonyms suffixed with "oxalate " map to the salt as PubChem CID 56959086
|
|
No information available. |
Summary of Clinical Use |
Following from reports of positive results in clinical trials [4], naloxegol has been approved for the treatment of opioid-induced constipation (or opioid-induced bowel dysfunction; OBD). |
Mechanism Of Action and Pharmacodynamic Effects |
Binding of opioid drugs to μ-opioid receptors in the enteric nervous system is believed to be responsible for opioid-induced constipation [2]. Naloxegol may alleviate this side effect by preventing the drug-receptor interaction at peripheral gut opioid receptors [1,3]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |